peginterferon alfa-2b

Known as: Pegylated Interferon Alpha-2b, Polyethylene Glycol IFN-A2b, PEG-IFN-a 2b 
A covalent conjugate of recombinant interferon alpha, subtype 2b, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
BACKGROUND & AIMS The risk of hepatocellular carcinoma (HCC) occurrence or recurrence following direct-acting antiviral (DAA… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Review
2017
Review
2017
Liposomes are the first nano drug delivery systems that have been successfully translated into real-time clinical applications… (More)
  • figure 3
  • figure 4
  • table 1
  • figure 5
  • figure 6
Is this relevant?
Review
2017
Review
2017
BACKGROUND & AIMS Hepatitis C virus (HCV) therapy that is highly efficacious, pangenotypic, with a high barrier to resistance and… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
Review
2017
Review
2017
An estimated 170 million persons worldwide have hepatitis C virus (HCV) infection (1), including 2.7 million to 3.9 million in… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin… (More)
  • figure 1
  • table 1
  • table 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND Several small studies have reported a lower response rate to interferon alfa among black patients with chronic… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Interferon-based regimens for the treatment of chronic hepatitis C have become increasingly effective and are able to eradicate… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2001
Highly Cited
2001
BACKGROUND A sustained virological response (SVR) rate of 41% has been achieved with interferon alfa-2b plus ribavirin therapy of… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
1998
Highly Cited
1998
BACKGROUND Only 15 to 20 percent of patients with chronic hepatitis C have a sustained virologic response to interferon therapy… (More)
Is this relevant?